The biotech company said in a statement that the data will be presented at the Conference on Retroviruses and Opportunistic Infections on March 7.
The company’s leronlimab candidate is a once-weekly injection designed to block HIV-1 from entering and infecting human cells by binding to the CCR5 receptor, a protein on the surface of white blood cells that is related to the immune system.
“CytoDyn’s commitment to providing groundbreaking therapeutic advances for those in need has never been stronger,” CEO Nader Pourhassan said. “We remain highly encouraged by the continued clinical and regulatory progress to bring the next generation HIV treatment to patients.”
The company is in the process of completing a biologics license application with the Food and Drug Administration for leronlimab, also known as PRO 140, as part of a combination with highly active antiretroviral therapies for HIV-infected patients.
Then, subject to the treatment's approval by the FDA as part of a combination therapy, CytoDyn plans to file for a label expansion for leronlimab as a monotherapy, providing the company can achieve positive results from a proposed Phase 3 trial.
The annual conference brings together clinical researchers from around the world to share the latest studies in the battle against HIV, AIDS and related infectious diseases. It will be held from March 4 to March 7 at the Washington State Convention Center in Seattle.
Contact Dennis Fitzgerald at [email protected]